



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

13 November 2025
EMADOC-1700519818-2579167
Committee for Medicinal Products for Human Use (CHMP)

Summary of opinion¹ (post authorisation)

Minjuvi tafasitamab

On 13 November 2025, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a change to the terms of the marketing authorisation for the medicinal product Minjuvi. The marketing authorisation holder for this medicinal product is Incyte Biosciences Distribution B.V.

The CHMP adopted a new indication as follows:²

MINJUVI is indicated in combination with lenalidomide followed by MINJUVI monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant (ASCT).

MINJUVI is indicated in combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) (Grade 1-3a) after at least one line of systemic therapy.

Detailed recommendations for the use of this product will be described in the updated summary of product characteristics (SmPC), which will be published on the EMA website in all official European Union languages after a decision on this change to the marketing authorisation has been granted by the European Commission.

¹ Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 days from adoption of the opinion

² New text in bold

